PATRICK P DELUCA
Pharmacy in Lexington, KY

4267449, May 12, 1981

Aug 14, 1979

6/066390

Patrick P. DeLuca - Lexington KY
L. David Butler - Lexington KY

The University of Kentucky Research Foundation - Lexington KY

G01T 1161, G09K 300

250303

A method for detecting leaky ampules filled with a liquid such as a parenteral solution. The ampules to be tested are immersed in a solution containing a short-lived radionuclide, and a pressure differential is imposed between the solution containing the radionuclide and the parenteral solution or other liquid contained in the ampules. The ampules are then removed from solution, decontaminated to remove any solution adhering to the outer surface and pores thereof, dried, and finally examined for electromagnetic radiation, preferably gamma radiation, emanating from the interior of the ampules which would indicate a leaky condition thereof.

7276359, Oct 2, 2007

Mar 12, 1999

09/622235

Shankar Musunuri - Downingtown PA, US
Patrick P. DeLuca - Lexington KY, US

Wyeth - Madison NJ

C12N 15/64, A61K 31/70

435 914, 4353201

A lyophilized polynucleotide composition contains at least one polynucleotide and at least one cryoprotectant, wherein the ratio of the polynucleotide to cryoprotectant is from about 0. 001 to about 1. 0 part by weight polynucleotide per 1. 0 part by weight of the cryoprotectant. This composition also contains from about 0. 5 weight percent to about (6) weight percent water, based on the total weight of the final lyophilized polynucleotide composition. The polynucleotide composition of this invention is characterized by enhanced stability, in that it retains at least 90% supercoil over a time period of at least (10) days at a temperature of about 37° C. The lyophilized polynucleotide composition also has improved solubility. An improved process for lyophilization of polynucleotides employs a specific primary drying cycle, that results in the above-described stable, lyophilized polynucleotide composition.

2008008, Apr 3, 2008

Aug 24, 2007

11/895481

Shankar Musunuri - Downingtown PA, US
Patrick DeLuca - Lexington KY, US

Wyeth - Madison NJ

C12N 15/00

435320100

A lyophilized polynucleotide composition contains at least one polynucleotide and at least one cryoprotectant, wherein the ratio of the polynucleotide to cryoprotectant is from about 0.001 to about 1.0 part by weight polynucleotide per 1.0 part by weight of the cryoprotectant. This composition also contains from about 0.5 weight percent to about (6) weight percent water, based on the total weight of the final lyophilized polynucleotide composition. The polynucleotide composition of this invention is characterized by enhanced stability, in that it retains at least 90% supercoil over a time period of at least (10) days at a temperature of about 37° C. The lyophilized polynucleotide composition also has improved solubility. An improved process for lyophilization of polynucleotides employs a specific primary drying cycle, that results in the above-described stable, lyophilized polynucleotide composition.

6306406, Oct 23, 2001

Jun 7, 1995

8/481155

Patrick P. Deluca - Lexington KY

University of Kentucky Research Foundation - Lexington KY

A61K 900, A61K 950

424400

A drug delivery system for controlled release of a protein or polypeptide comprising a hydrophobic biodegradable polymer and a protein or polypeptide. A physical interaction is present between the polymer and the protein or polypeptide, thus, allowing protection and controlled release of the protein or polypeptide in-vivo. The drug delivery system may be prepared by a polymer precipitation technique or a microsphere technique.

2011001, Jan 20, 2011

Sep 5, 2008

12/205303

Ahmad Malkawi - Lexington KY, US
Patrick DeLuca - Lexington KY, US
George Digenis - Louisville KY, US

US WorldMeds, LLC - Louisville KY

A61K 31/4168, A61K 31/4166, C07D 405/12

514390000, 514392000, 548316100

The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

2002005, May 2, 2002

Sep 4, 2001

09/944369

Patrick DeLuca - Lexington KY, US

A61F002/00

424/426000, 424/484000

A drug delivery system for controlled release of a protein or polypeptide comprising a hydrophobic biodegradable polymer and a protein or polypeptide. A physical interaction is present between the polymer and the protein or polypeptide, thus, allowing protection and controlled release of the protein or polypeptide in-vivo. The drug delivery system may be prepared by a polymer precipitation technique or a microsphere technique.

2009030, Dec 10, 2009

Oct 31, 2008

12/290575

David R. Worthen - Lexington KY, US
David Johnson - Owensboro KY, US
Patrick P. DeLuca - Lexington KY, US
Paolo Blasl - Belmonte Picano, IT

A24B 15/00

131274

A method for producing flavoring materials consisting of a flavor and a simple matrix material that are GRAS or approved for use in food, and that will be stable under extremely adverse conditions, greater than 50% moisture, high pH, high temperature stability (60° C.), yet be released in the oral cavity; without the use of organic solvents, and with the use of inexpensive materials and unsophisticated equipment.

2007012, May 31, 2007

Mar 19, 2004

10/549760

Patrick Deluca - Lexington KY, US
Ge Jiang - Durham NC, US
Byung Woo - Schaumburg IL, US

UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION - Lexington KY

A61K 38/22, A61K 38/28, A61K 38/18, A61K 38/21, A61K 9/14, A61K 9/50

424490000, 514002000, 514003000, 514015000, 424085400, 424046000

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

2009025, Oct 8, 2009

Dec 4, 2008

12/315603

Francesca Selmin - Milan, IT
Paolo Blasi - Belmonte Piceno, IT
David R. Worthen - Lexington KY, US
David Johnson - Owensboro KY, US
Patrick P. DeLuca - Lexington KY, US

A61K 31/44, A24B 15/36, B05D 3/02, A61K 47/30, A61P 43/00, C08L 1/00, C08L 1/26, A23L 1/226

514343, 131277, 427384, 514777, 10616301, 1061721, 426650

A fast-dissolving film for use as a platform for the delivery of material to the oral cavity, comprising a film forming agent; a plasticizing agent; and a fast-dissolving, water-soluble agent; and methods for producing same.

4818542, Apr 4, 1989

Mar 31, 1986

6/846513

Patrick P. DeLuca - Lexington KY
Motoko Kanke - Fukuyama, JP
Toyomi Sato - Tokyo, JP
Hans G. Schroeder - Encinitas CA

The University of Kentucky Research Foundation - Lexington KY

A61K 916, A61K 950, A61K 952, B01J 1302

424491

Controlled release drug delivery systems comprised of spherical microporous polymeric network of interconnecting channels containing pore incorporated drugs or other agents wherein the drugs or agents are confined within the pore channel are described. Also disclosed are processing parameters in connection with the novel method of the invention for obtaining drug delivery systems especially suited for parenteral as well as oral administration.